Back to results
US 6,551,992 B1Granted
Stable insulin formulations
AssigneeEli Lilly and Company
InventorsMichael Rosario DeFelippis, Michael Allen Dobbins, Bruce Hill Frank, Shun Li, Dawn Marie Rebhun
Life of this patent
Estimating the term…
Abstract
The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.
Claims23
A solution formulation comprising:
- a physiologically tolerated buffer selected from the group consisting of TRIS and arginine;
- a monomeric insulin analog;
- zinc;
- and a phenolic preservative,
- wherein the formulation is a solution formulation.
2 more elements
A stable, soluble formulation of a monomeric insulin analog, for use in a continuous infusion system, consisting essentially of:
- an isotonicity agent;
- a buffer selected from the group consisting of TRIS and arginine;
- zinc;
- and a phenolic preservative.
1 more element
Dependencies are inferred from the claim text.